Contemporary Treatment of Endometrial Cancer: An In the Clinic Activity




Provided by Integrity Continuing Education, Inc.


This educational activity is supported by educational grants from Eisai Inc., GlaxoSmithKline, and Merck Sharp & Dohme Corp.


The treatment options for advanced or recurrent endometrial cancer (EC) have changed dramatically in the last five years. Molecular testing to identify patients that could benefit from targeted treatments are now recommended for all patients.  Choosing the optimal treatment can be complex as treatment planning must consider molecular signatures, safety and efficacy data, patient and tumor characteristics, and guideline recommendations.  

In this edition of In the Clinic, Drs. Murphy and Westin will unpack the latest clinical trial data and review best practices for approaching treatment for these patients.


Martina Murphy, MD
Associate Professor of Medicine
Director, UFCOM Introduction to Clinical Medicine 1A & 1B
Program Director
Hematology/Oncology Fellowship
University of Florida
Gainesville, Florida


Shannon N. Westin, MD, MPH
Associate Professor of Medicine
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas


Case Development Faculty

Michaela Onstad-Grinsfelder, MD, MPH
Assistant Professor
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas


Release date: June 30, 2022
Expiration date: June 30, 2023
Estimated time to complete activity: 60 minutes



This educational activity has been designed to meet the needs of medical and gynecologic oncologists, physician assistants, and nurse practitioners who treat and manage patients with gynecologic malignancies, with a focus on the community-based clinician.


Upon completion of this educational activity, participants should be able to:

  • Elucidate the necessity for genetic and molecular testing to aid in selecting appropriate monotherapeutic or combination treatment options to improve survival outcomes in patients with advanced or recurrent EC
  • Devise a strategy to incorporate recently approved or emerging treatment options for patients with advanced or recurrent EC based on clinical trial findings
  • Identify and monitor for, as well as manage and mitigate against, adverse reactions that can be caused by treatments that were recently approved for advanced or recurrent EC

There are no fees for participating and receiving CME credit for this activity. During the period of June 30, 2022 through June 30, 2023, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.




Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Martina C. Murphy, MD does not have any real or apparent conflicts to disclose.

Michaela Onstad-Grinsfelder, MD, MPH, does not have any real or apparent conflicts to disclose.

Shannon N. Westin, MD, MPH
Grants/Contracts: AstraZeneca, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, GlaxoSmithKline, Mereo, Novartis, OncXerna, Roche/Genentech, Zentalis
Consulting Fees: Agenus, AstraZeneca, Caris, Clovis Oncology, Eisai, EQRx, GlaxoSmithKline, ImmunoGen, Karyopharm, Lilly, Merck, Mereo, Mersana, Roche/Genentech, Vincerx, Zentalis

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest